|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
LortetTieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eroles P, Bosch A, Pérez-Fidalgo JA and
Lluch A: Molecular biology in breast cancer: Intrinsic subtypes and
signaling pathways. Cancer Treat Rev. 38:698–707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. Gallen international expert consensus on the primary
therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Byler S, Goldgar S, Heerboth S, Leary M,
Housman G, Moulton K and Sarkar S: Genetic and epigenetic aspects
of breast cancer progression and therapy. Anticancer Res.
34:1071–1077. 2014.PubMed/NCBI
|
|
5
|
Kontorovich T, Levy A, Korostishevsky M,
Nir U and Friedman E: Single nucleotide polymorphisms in miRNA
binding sites and miRNA genes as breast/ovarian cancer risk
modifiers in Jewish high-risk women. Int J Cancer. 127:589–597.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baffa R, Fassan M, Volinia S, O'Hara B,
Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM and
Rosenberg A: MicroRNA expression profiling of human metastatic
cancers identifies cancer gene targets. J Pathol. 219:214–221.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matamala N, Vargas MT, GonzalezCampora R,
Minambres R, Arias JI, Menendez P, AndresLeon E, GomezLopez G,
Yanowsky K, CalveteCandenas J, et al: Tumor microRNA expression
profiling identifies circulating microRNAs for early breast cancer
detection. Clin Chem. 61:1098–1106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Banzhaf-Strathmann J and Edbauer D: Good
guy or bad guy: The opposing roles of microRNA 125b in cancer. Cell
Commun Signal. 12:302014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferracin M, Bassi C, Pedriali M, Pagotto
S, D'Abundo L, Zagatti B, Corrà F, Musa G, Callegari E, Lupini L,
et al: miR-125b targets erythropoietin and its receptor and their
expression correlates with metastatic potential and ERBB2/HER2
expression. Mol Cancer. 12:1302013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Yan LX, Wu QN, Du ZM, Chen J,
Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, et al: miR-125b is
methylated and functions as a tumor suppressor by regulating the
ETS1 proto-oncogene in human invasive breast cancer. Cancer Res.
71:3552–3562. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Feliciano A, Castellvi J, ArteroCastro A,
Leal JA, Romagosa C, HernandezLosa J, Peg V, Fabra A, Vidal F,
Kondoh H, et al: miR-125b acts as a tumor suppressor in breast
tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and
MEGF9. PLoS One. 8:e762472013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scott GK, Goga A, Bhaumik D, Berger CE,
Sullivan CS and Benz CC: Coordinate suppression of ERBB2 and ERBB3
by enforced expression of micro-RNA miR-125a or miR-125b. J Biol
Chem. 282:1479–1486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang F, Zhang R, He Y, Zou M, Guo L and Xi
T: MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7
and MDA-MB-231 breast cancer cells. PLoS One. 7:e354352012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang HJ, Guo YQ, Tan G, Dong L, Cheng L,
Li KJ, Wang ZY and Luo HF: miR-125b regulates side population in
breast cancer and confers a chemoresistant phenotype. J Cell
Biochem. 114:2248–2257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi
Y, Xiong W, Li G, Lu J, Fodstad O, et al: MicroRNA-125b confers the
resistance of breast cancer cells to paclitaxel through suppression
of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J
Biol Chem. 285:21496–21507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang H, Tan G, Dong L, Cheng L, Li K, Wang
Z and Luo H: Circulating MiR-125b as a marker predicting
chemoresistance in breast cancer. PLoS One. 7:e342102012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan SQ, Ma J, Zhou J, Xiong W, Xiao BY,
Zhang WL, Tan C, Li XL, Shen SR, Zhou M, et al: Differential
expression of Epstein-Barr virus-encoded RNA and several
tumor-related genes in various types of nasopharyngeal epithelial
lesions and nasopharyngeal carcinoma using tissue microarray
analysis. Hum Pathol. 37:593–605. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakanishi H, Taccioli C, Palatini J,
FernandezCymering C, Cui R, Kim T, Volinia S and Croce CM: Loss of
miR-125b-1 contributes to head and neck cancer development by
dysregulating TACSTD2 and MAPK pathway. Oncogene. 33:702–712. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Henson BJ, Bhattacharjee S, O'Dee DM,
Feingold E and Gollin SM: Decreased expression of miR-125b and
miR-100 in oral cancer cells contributes to malignancy. Genes
Chromosomes Cancer. 48:569–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu LH, Li H, Li JP, Zhong H, Zhang HC,
Chen J and Xiao T: miR-125b suppresses the proliferation and
migration of osteosarcoma cells through down-regulation of STAT3.
Biochem Biophys Res Commun. 416:31–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Smits M, Wurdinger T, van het Hof B,
Drexhage JA, Geerts D, Wesseling P, Noske DP, Vandertop WP, de
Vries HE and Reijerkerk A: Myc-associated zinc finger protein (MAZ)
is regulated by miR-125b and mediates VEGF-induced angiogenesis in
glioblastoma. FASEB J. 26:2639–2647. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He J, Xu Q, Jing Y, Agani F, Qian X,
Carpenter R, Li Q, Wang XR, Peiper SS, Lu Z, et al: Reactive oxygen
species regulate ERBB2 and ERBB3 expression via miR-199a/125b and
DNA methylation. EMBO Rep. 13:1116–1122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bousquet M, Harris MH, Zhou B and Lodish
HF: MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA.
107:21558–21563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Willimott S and Wagner SD: miR-125b and
miR-155 contribute to BCL2 repression and proliferation in response
to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem.
287:2608–2617. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xia HF, He TZ, Liu CM, Cui Y, Song PP, Jin
XH and Ma X: MiR-125b expression affects the proliferation and
apoptosis of human glioma cells by targeting Bmf. Cell Physiol
Biochem. 23:347–358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Le MT, Teh C, ShyhChang N, Xie H, Zhou B,
Korzh V, Lodish HF and Lim B: MicroRNA-125b is a novel negative
regulator of p53. Genes Dev. 23:862–876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bousquet M, Quelen C, Rosati R, MansatDe
MV, La Starza R, Bastard C, Lippert E, Talmant P,
Lafage-Pochitaloff M, Leroux D, et al: Myeloid cell differentiation
arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid
leukemia with the t(2;11)(p21;q23) translocation. J Exp Med.
205:2499–2506. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chapiro E, Russell LJ, Struski S, Cavé H,
Radford-Weiss I, Valle VD, Lachenaud J, Brousset P, Bernard OA,
Harrison CJ and Nguyen-Khac F: A new recurrent translocation
t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell
progenitor acute lymphoblastic leukemia. Leukemia. 24:1362–1364.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fassan M, Pizzi M, Realdon S, Balistreri
M, Guzzardo V, Zagonel V, Castoro C, Mastracci L, Farinati F, Nitti
D, et al: The HER2-miR125a5p/miR125b loop in gastric and esophageal
carcinogenesis. Hum Pathol. 44:1804–1810. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He J, Jing Y, Li W, Qian X, Xu Q, Li FS,
Liu LZ, Jiang BH and Jiang Y: Roles and mechanism of miR-199a and
miR-125b in tumor angiogenesis. PLoS One. 8:e566472013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yagishita S, Fujita Y, Kitazono S, Ko R,
Nakadate Y, Sawada T, Kitamura Y, Shimoyama T, Maeda Y, Takahashi
F, et al: Chemotherapy-regulated microRNA-125-HER2 pathway as a
novel therapeutic target for trastuzumab-mediated cellular
cytotoxicity in small cell lung cancer. Mol Cancer Ther.
14:1414–1423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shang C, Lu YM and Meng LR: MicroRNA-125b
down-regulation mediates endometrial cancer invasion by targeting
ERBB2. Med Sci Monit. 18:BR149–BR155. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu
M, Tepper CG, Evans CP, Kung HJ and White RW deVere: An
androgen-regulated miRNA suppresses Bak1 expression and induces
androgen-independent growth of prostate cancer cells. Proc Natl
Acad Sci USA. 104:19983–19988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schwarzenbacher D, Balic M and Pichler M:
The role of microRNAs in breast cancer stem cells. Int J Mol Sci.
14:14712–14723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Le MT, ShyhChang N, Khaw SL, Chin L, Teh
C, Tay J, O'Day E, Korzh V, Yang H, Lal A, et al: Conserved
regulation of p53 network dosage by microRNA-125b occurs through
evolving miRNA-target gene pairs. PLoS Genet. 7:e10022422011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vilquin P, Donini CF, Villedieu M, Grisard
E, Corbo L, Bachelot T, Vendrell JA and Cohen PA: MicroRNA-125b
upregulation confers aromatase inhibitor resistance and is a novel
marker of poor prognosis in breast cancer. Breast Cancer Res.
17:132015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zheng Y, Li S, Boohaker RJ, Liu X, Zhu Y,
Zhai L, Li H, Gu F, Fan Y, Lang R, et al: A microRNA expression
signature in taxane-anthracycline-based neoadjuvant chemotherapy
response. J Cancer. 6:671–677. 2015. View Article : Google Scholar : PubMed/NCBI
|
